ClinicalTrials.gg
RecruitingNCT04802135IMPROVEUpdated Nov 20, 2025

Creation of a Register of Patients With Neonatal-onset Epileptic Encephalopathy

An observational study in Epileptic Encephalopathy, sponsored by Assistance Publique Hopitaux De Marseille. Recruiting at 15 sites in France. Per ClinicalTrials.gov, last updated 2025-11-20.

Sponsored by Assistance Publique Hopitaux De Marseille · Observational

How we know

From the registry’s dates

  • Started Mar 2021; still recruiting 5 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
200
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Epilepsy by Assistance Publique Hopitaux De Marseille — 6 open to participants now, 7 under way, none of them phase 3. Epilepsy · Assistance Publique Hopitaux De Marseille.

Started
2021
with 5 others
Observational
3 of 18
3 open now
Registered
12th of 18
by date

Among the 18 studies in Epilepsy by Assistance Publique Hopitaux De Marseille, this one is one of 6 that started in 2021, is one of 3 observational ones, and was the 12th registered.

Epilepsy

1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.

Browse Epilepsy studies →

Open to participants now

6 of the 18 studies in Epilepsy by Assistance Publique Hopitaux De Marseille are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 284 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Epilepsy by Assistance Publique Hopitaux De Marseille, or all of them as a file.
02

Study summary

Electrical activity emerges in the third trimester of pregnancy, plays an important role in the construction of cortical maps, and is impaired in patients with severe early epileptic encephalopathies (EOEE). EOEE are rare and severe epileptic syndromes characterized by epilepsy that begins within the first three months of life and is associated with rapid deterioration of motor, cognitive and behavioral skills.

There is a genetic basis for the EOEE. Together with other laboratories, the investigators have identified de novo pathogenic variants in the KCNQ2 gene encoding the Kv7.2 subunit of the Kv7 / M potassium channel, a channel known to control neuronal excitability in the brain and spinal cord. via the current M (IM). Pathogenic variants of the KCNQ2 gene represent the main cause of EOEE and the term KCNQ2-related epileptic encephalopathy (KCNQ2-REE) is now used to define this condition.

KCNQ2-REE patients have a remarkably homogeneous phenotype at the start, with epilepsy that begins in the first days after birth, seizures that result in tonic muscle spasms that last from 1 to 10 seconds, and an interictal EEG called "suppression-burst". "That is, paroxysmal bursts of activity interspersed with periods of electrical silence. In this group, more than 50% of the patients present a remission of the epilepsy and a quasi-normalization of the EEG which can occur a few weeks to several months after the onset of the seizures. Despite this positive evolution in terms of seizures, the developmental progression is abnormal and the phenotype is severe with an absence of language, autistic behavior and a subsequent development of motor disorders such as diplegia, spasticity, ataxia or dystonia.

The ambition of this project is to increase knowledge of epileptic encephalopathies linked to KCNQ2 at the clinical and molecular levels, to decipher the pathophysiological mechanisms and to propose therapeutic strategies.

This project aims to better describe the clinical, EEG, imaging, developmental and long-term follow-up characteristics of patients carrying the KCNQ2 mutation identified in the laboratory.

03

Conditions studied

  • Epileptic Encephalopathy

Browse trials for

Keywords

  • EOEE
  • epilepsy
  • KCNQ2
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Retrospective observational study initially then prospective with inclusion of all patients with a KCNQ2-REE whose diagnosis was made in the EPIGENE network

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Epilepsy beginning before 1 month of life, and requiring the initiation of anti-epileptic treatment
  • Without occasional cause
  • Without brain malformation explaining epilepsy
  • No opposition from parents / guardians
  • Possibility for parents to complete parent questionnaires

Exclusion criteria

Exclusion Criteria:

  • Neonatal attacks of occasional cause (glycemic disorder, infection, etc.)
  • Acquired neonatal epilepsy (post-anoxic encephalopathy, stroke sequelae, etc.)
  • Neonatal epilepsy related to a brain malformation
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
200 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes

Interventions

  • OtherSurvey

    directive questionnaire administered during an individual face-to-face interview

06

What researchers measure

Primary outcomes

  1. importance of the developmental disorder

    Developmental quotient

    Time frame: Month 36

  2. definition of the active phase of epilepsy

    Presence of at least monthly seizures and interictal EEG showing paroxysmal abnormalities

    Time frame: Month 36

07

Study locations

2 of 15 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2021 (actual). Primary completion is estimated for Sep 2029, 102 months after the start.

Of 193 non-industry observational studies under Epilepsy, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 179. This study's planned 102 months is above that.

Counting every sponsor, half of 231 studies reached it within 59 months; a quarter within 24 and three quarters within 109.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2021
First posted
Mar 17, 2021
StartActual
Mar 6, 2021
Primary completionEst.
Sep 2029
CompletionEst.
Sep 2032
Last update
Nov 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04802135
Responsible party
Sponsor
First posted
Mar 17, 2021
Start date
Mar 6, 2021
Primary completion
Sep 2029 (estimated)
Completion
Sep 2032 (estimated)
Last update
Nov 20, 2025

Study contacts

Mathieu Milh
Contact
mathieu.milh@ap-hm.fr
0491322903 ext. 33
Jean Olivier Arnaud
study director · Assistance Publique - Hôpitaux de Marseille

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion